Real-World, Observational Study Assessing The Proportion Of Leukapheresed Patients with Relapsed and Refractory Multiple Myeloma That Receive Infusion of Idecabtagene Vicleucel (CA089-1097)

First published 21/02/2025

Last updated 21/02/2025

EU PAS number:

EUPAS1000000456

Study

Planned

Download as PDF

Documents

Study protocol

No information provided.

Study results

No information provided.

Study report

No information provided.

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

No information provided.

Real-World, Observational Study Assessing The Proportion Of Leukapheresed Patients with Relapsed and Refractory Multiple Myeloma That Receive Infusion of Idecabtagene Vicleucel (CA089-1097)

Secondary tabs

Share this page